Great to see this first approval to commence the Phase III.
An untouched $1B per annum market is at the door step, and another $600M from the US in due time, with our CSO an author of clinical and diagnostic guidelines to help market penetration, MST have peak sales of $396Mpa USD.
$35M MC with $31M cash, for an EV of $4M has to be one of the cheapest active Phase III on the listed market. For what could be $396Mpa peak sales as per MST report.
With $26M raised at $1.33 per share with Andrew Twiggy Forrest pouring in $5M, prices of $0.50c represent comparative value.
Exciting times to watch this one unfold!
Ann: Invex Receives UK Approval to Commence Phase III Trial, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
8.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.237M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28352 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.6¢ | 16835 | 2 |
View Market Depth
| Last trade - 10.04am 28/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable